Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 15/20 | 0.58 |
| ▸ | CA1 | P00915 | 14/20 | 0.58 |
| ▸ | CA2 | P00918 | 14/20 | 0.58 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.57 |
| ▸ | ALB | P02768 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13062332 | 0.97 | CA9 (0.57) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13012837 | 0.94 | CA9 (0.60) | CA9CA1CA2CA12CA14 | |
| SCHEMBL22414019 | 0.94 | CA9 (0.54) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21610017 | 0.94 | CA9 (0.53) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14306442 | 0.93 | CA9 (0.53) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21610016 | 0.93 | FOLH1 (0.54) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17793598 | 0.92 | FOLH1 (0.64) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19354963 | 0.92 | CA9 (0.53) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13424228 | 0.91 | FOLH1 (0.58) | CA9CA1CA2CA12CA14 | |
| SCHEMBL22100260 | 0.91 | FOLH1 (0.59) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190002861-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-9951324-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2011106639-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322741-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA9 103/4885CA1 397/4885CA2 1844/4885 |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA9 103/4885CA1 397/4885CA2 1844/4885 |
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CA9 103/4885CA1 397/4885CA2 1844/4885 |
| US-20190002861-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA9 103/4885CA1 397/4885CA2 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.